Premas Life Sciences and Sphere Bio Unite to Advance Single-Cell Research in South Asia
India PR Distribution
New Delhi [India], May 6: Premas Life Sciences Pvt. Ltd. (PLS), a pioneering enabler of life science innovations in India, has announced a strategic collaboration with Sphere Bio, a global leader in picodroplet-based microfluidic technologies for functional single-cell analysis. This partnership represents a significant leap in bringing transformative, next-generation platforms to scientists and researchers in India and Bangladesh. The collaboration is rooted in a shared vision: empowering biopharma, biotech, and academic communities with cutting-edge tools that accelerate discovery and drive impactful science. With this alliance, Premas will bring Sphere Bio's high-performance solutions - including their flagship Cyto-Mine® platform and a growing assay portfolio - closer to researchers in South Asia, supported by localized technical expertise and seamless implementation support.
Sphere Bio, formerly known as Sphere Fluidics, is widely recognized for its innovations in single-cell and picodroplet microfluidics. Their technologies enable ultra-high-throughput analysis, sorting, and isolation of individual cells - critical for applications such as antibody discovery, cell line development, and advanced cell therapy research. These platforms are currently used by leading pharma companies and research institutions around the world to enhance the speed and accuracy of biologic development.
For Premas Life Sciences, this partnership is a natural extension of its mission to democratize access to advanced life science tools. Over the last 18 years, PLS has built a strong legacy of introducing globally benchmarked technologies to India's scientific ecosystem - spanning genomics, proteomics, bioinformatics, and diagnostics. Their ability to not only introduce but also embed technologies through technical training, application support, and long-term scientific partnerships makes them uniquely positioned to amplify the impact of Sphere Bio's offerings.
"India is entering a new era of biomedical innovation, with increased investments in biosimilars, vaccines, and cell and gene therapies. This collaboration with Sphere Bio allows us to deliver the kind of scientific capabilities that can transform how research is done in this region--faster, more precisely, and with greater reproducibility. With the government's strong push through initiatives like the Bio-E3 policy, PRIP scheme, and its vision for bio foundries, we believe technologies like Sphere Bio's Cyto-Mine® will play a crucial role in accelerating antibody discovery and cell line development, further strengthening the 'Made in India' biotech ecosystem. We're excited to co-create a future where access to such platforms is not a barrier but a baseline." said Praveen Gupta, Managing Director of Premas Life Sciences.
Sphere Bio echoed this optimism. "We see South Asia as a region with enormous scientific potential. Our partnership with Premas is about more than market access - it's about long-term impact. Premas brings deep local understanding, technical know-how, and a genuine commitment to enabling discovery. Together, we aim to catalyse the next wave of breakthroughs in biologics and personalized medicine." said Dale Levitzke, CEO of Sphere Bio
"Our partnership with Premas Life Sciences is a key milestone in our mission to make cutting-edge single-cell technologies more accessible across the APAC region. India and Bangladesh represent rapidly growing innovation hubs, and we see immense potential in empowering local researchers with tools that meet global standards. Premas brings deep market understanding, strong scientific engagement, and a track record of successful technology integration--making them an ideal partner to drive regional adoption and impact." said Jay Manikandan, VP Commercial (APAC), Sphere Bio
This alliance comes at a pivotal time, as the biotech landscape in India and Bangladesh rapidly evolves with government backing, rising R & D investment, and a growing scientific workforce. As demand for next-gen therapeutics increases, so does the need for high-resolution, scalable tools--precisely what Sphere Bio delivers. Together, Premas and Sphere Bio are building a scientific bridge between global innovation and regional potential. Beyond product access, the partnership offers localized support, training, and tailored solutions aligned with international standards. It sets a new benchmark for how advanced technologies can be effectively introduced and scaled in emerging biotech markets.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
4 hours ago
- Hindustan Times
Govandi residents accuse MPCB of undervaluing environmental violations by biomedical waste facility
MUMBAI: Residents of Govandi have accused the Maharashtra Pollution Control Board (MPCB) of grossly underreporting and mishandling environmental violations by SMS Envoclean Pvt. Ltd., which operates a biomedical waste treatment facility in the area. A biomedical waste treatment facility is a specialised center that handles, processes, and disposes of hazardous waste from healthcare and research facilities, such as used syringes, bandages, surgical instruments, pathological waste, pharmaceuticals, and materials contaminated with blood, bodily fluids, or infectious agents. In a fresh application filed before the National Green Tribunal (NGT), a specialised judicial body in India established to address environmental disputes, on June 2, the Govandi New Sangam Welfare Society alleged that MPCB failed to impose appropriate environmental penalties on the facility, despite repeated violations of the Bio-Medical Waste Management Rules, 2016 (BMWM Rules). The Society claims that the MPCB ignored key violations such as untreated effluent discharge, improper handling of biomedical waste, and manipulation of emissions data while calculating Environmental Damage Compensation (EDC). Citing the Polluter Pays and Precautionary Principles, which requires polluters to bear the costs of pollution prevention, control, and restoration, the petition demands a new, legally sound assessment of the environmental damage and seeks personal accountability of MPCB officials for allegedly suppressing evidence and failing to perform their statutory duties. The society pointed to several complaints it had made in the past, flagging serious concerns over toxic emissions and adverse health impacts from the plant. Following inspections, the MPCB issued closure directions in July 2019, confirming violations of the BMWM Rules. However, despite this, the board imposed no penalty and calculated a compensation of just ₹14.22 lakh—an amount the petitioners say grossly favours the polluter. Dissatisfied with the inaction, the society initially filed a public interest litigation in the Bombay High Court. On September 11, 2023, the High Court directed the petitioners to approach the NGT for suitable remedies. In its plea, the society accused the MPCB of deliberately excluding crucial evidence of non-compliance, including failure to meet treated wastewater standards and delays in disposing of biomedical waste within the mandated 48-hour period. 'MPCB chose to disregard these key violations for reasons best known to them,' the petition closure notice issued by MPCB itself, dated July 6, 2019, documented several infractions- failure to segregate waste as per the 2016 Rules, poor maintenance of biomedical waste records, unwashed transport vehicles at the site, and transportation vehicles lacking mandatory biohazard symbols. 'Despite these glaring lapses, MPCB has under-calculated the compensation and misled the tribunal,' the petition alleged. The residents further invoked the Central Pollution Control Board's 2019 guidelines, which require enhanced penalties for repeat violations—guidelines that MPCB allegedly failed to apply. This, the petition claims, has made such violations economically viable for offending the society alleged that MPCB excluded 267 days during the COVID-19 pandemic and another 395 days in 2020–21 from its compensation calculation—periods during which violations had occurred. Calling for the application of the strict and absolute liability principle under environmental law, the society urged the NGT to direct MPCB to reassess and impose a fair and accurate EDC on the polluter.
Business Standard
15 hours ago
- Business Standard
G.C Chemie Pharmie: Four Decades of Innovation and Trust in Pharmaceuticals and Nutraceuticals
India PR Distribution Mumbai (Maharashtra) [India], June 6: G.C Chemie Pharmie Pvt. Ltd. (GCCPL), a pioneer in India's pharmaceutical, nutraceutical, functional foods, and biopharmaceutical sectors, proudly celebrates over 44 years of innovation and service excellence. Founded in 1981 by visionary entrepreneur Gautam Shah, GCCPL has evolved into a globally connected and innovation-driven enterprise known for its commitment to trust, transparency, and quality. What began as an API trading and distribution firm has transformed into a diversified pharmaceutical powerhouse. GCCPL's impressive timeline of achievements includes: - 2009/2010: Acquisition of Eagle Chemical Works, establishing its own API manufacturing capabilities - 2009: Release of its first vaccine, marking a significant milestone in biopharmaceuticals - 2010/2011: Launch of its P2P division, introducing affordable medicines to the Indian market -2018: Entry into the sports nutrition space - 2022: Creation of a preventive healthcare division with a focus on gynecology and orthopedics - 2023: Establishment of a dedicated vaccine division to expand immunization solutions Driven by a mission to lead through innovative thinking and technology adoption, GCCPL delivers tailored solutions across pharmaceutical, nutraceutical, and functional food categories. The company continues to differentiate itself through its strong regulatory acumen, cutting-edge R & D, and a global network of manufacturing and distribution partners. "At GCCPL, innovation is not a buzzword--it's the foundation of our growth strategy," said Founder and Chairman Gautam Shah. "We're proud to be one of India's few private companies to bring the pneumococcal vaccine to the domestic market, second only to Pfizer." Recent product highlights include UC-II®, a patented undenatured type II collagen supplement, and Pylopass™, a breakthrough strain-based probiotic--both showcasing GCCPL's commitment to introducing clinically backed, innovative health solutions to India. With a sterling reputation for regulatory compliance, deep market research, and financial integrity--as affirmed by CRISIL's highest rating A2+ GCCPL stands as a trusted partner for businesses and healthcare providers seeking reliable, next-generation healthcare products. About G.C Chemie Pharmie Pvt. Ltd. Founded in 1981, GCCPL is an Indian-based pharmaceutical and nutraceutical company with a global footprint. Known for its reliability, innovation, and commitment to quality, GCCPL offers customized, technology-driven healthcare solutions to meet the evolving needs of today's market. The company maintains a strong presence in vaccines, preventive care, functional foods, and advanced supplements.
The Wire
20 hours ago
- The Wire
CHARGE ZONE® Marks World Environment Day with ‘Shwa', Bringing Climate and Culture to India's Highway Supercharging Network
India | June 6, 2025 — On the occasion of World Environment Day, CHARGE ZONE®, India's largest electric vehicle charging network, launches 'Shwa', a visionary public art initiative that reimagined EV Supercharging stations as cultural landmarks bringing together sustainability, community, and creativity through large scale murals. Developed in collaboration with acclaimed and emerging Indian artists, … Continue reading "CHARGE ZONE® Marks World Environment Day with 'Shwa', Bringing Climate and Culture to India's Highway Supercharging Network"
